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Background: Mutations in the Mevalonate Kinase gene (MVK) are causes of a rare autoinflammatory disease:
Mevalonate Kinase Deficiency and its more acute manifestation, Mevalonic Aciduria. The latter is characterized, among
other features, by neuroinflammation, developmental delay and ataxia, due to failed cerebellar development or
neuronal death through chronic inflammation. Pathogenesis of neuroinflammation in Mevalonate Kinase Deficiency
and Mevalonic Aciduria has not yet been completely clarified, however different research groups have been
suggesting the inflammasome complex as the key factor in the disease development. A strategy to mimic this
disease is blocking the mevalonate pathway, using HMG-CoA reductase inhibitors (Statins), while knock-out mice
for Mevalonate Kinase are non-vital and their hemyzygous (i.e only one copy of gene preserved) littermate display
almost no pathological features.
Findings: We sought to generate a murine cellular model closely resembling the pathogenic conditions found
in vivo, by direct silencing of Mevalonate Kinase gene. Knockdown of Mevalonate Kinase in a murine microglial
cellular model (BV-2 cells) results in neither augmented NALP3 expression nor increase of apoptosis. On the contrary,
statin treatment of BV-2 cells produces an increase both in Mevalonate Kinase and NALP3 expression.
Conclusions: MKD deficiency could be due or affected by protein accumulation leading to NALP3 activation, opening
novel questions about strategies to tackle this disease.
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Mevalonate Kinase is a key enzyme in the cholesterol
biosynthetic pathway and is responsible for converting
mevalonic acid to mevalonate-5-phosphate, an early
intermediate in sterol and isoprenoid synthesis. Muta-
tions in the MVK gene (12q24) encoding Mevalonate
Kinase enzyme (MVK) cause Mevalonate Kinase Defi-
ciency (MKD, OMIM #260920) and its more severe form,
Mevalonic Aciduria (MA, OMIM #610377). The latter is
characterized by recurrent attacks of fever, developmental
delay, ataxia, dysmorphic features, failure to thrive, cata-
racts, and retinal dystrophy. The prognosis is poor: few
patients survive until adolescence and more than 50% of
them succumb to an inflammatory crisis during the first
years of life [1]. One of the characteristics of this disease is
cerebellar atrophy, due to neuronal apoptosis [2].* Correspondence: fulvio.celsi@burlo.trieste.it
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unless otherwise stated.Although the genetic defects are well known and char-
acterized, the pathogenic mechanism remains elusive, and
treatment of the disease remains mainly supportive, with
poor efficacy. For an evidence-based therapy, it is crucial
to determine the exact pathogenic mechanisms occurring
in the disease. Animals or cell-based models are thus ne-
cessary; in the past a mouse model of MVK deficiency was
generated [3] however it was unable to correctly represent
the pathology. Then a cellular model have been developed,
where the mevalonate pathway is pharmacologically
targeted using HMG-CoA blockers (statins), mimicking
some of the inflammatory features observed in cells
from patients [4]. Using this strategy, our group and
other authors have found that, in different cell lines,
NALP3 inflammasome activation is responsible for ini-
tiating inflammation [4-6]. This multi-molecular complex,
constituted by NALP3, ASC and Caspase-1, cleaves pro-
IL-1β to release its active form, starting inflammation [7].
Accordingly, NALP3 activation could represent a possible
starting point for MA pathogenic progression. A numberis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Celsi et al. Journal of Inflammation  (2015) 12:7 Page 2 of 5of issues need to be clarified, such as how the inflamma-
some pathway is incorrectly activated in cells presenting
the pathological mutations. In the attempt to better mimic
MA pathology we developed a novel murine cell model in
which MVK expression is specifically down-regulated,
using the silencing RNA (siRNA) technology. We then
compared the results obtained by siRNA transfection with
those achieved with Lovastatin and LPS treatment, in
order to determine the better model suitable for mimick-
ing the pathologic condition.Materials and methods
BV-2 cell culture, transfection and treatment
During febrile attacks, MVK deficient patients experience
an acute phase response showing increased plasma levels
of IL-1β, IL-6 and TNF-α, and elevated urinary leukotri-
ene E4 and neopterin excretion [8,9]. These observations
have suggested that activation of macrophages might play
a crucial pathogenic role, during as well as between at-
tacks [10]. Evidences suggest that also the nervous system
is involved in the most severe forms of MKD and that
microglia might be activated consequently triggering
neuroinflammation [11]. For these reasons, we used the
murine microglial BV-2 cell line for the MVK RNAi
experiments.
The microglial cell line BV-2 was maintained in
RPMI medium (Euroclone) supplemented with 10%
FBS, Pen/Strep. All experiments were conducted in
passages between 2 and 8-10 to avoid effects due to
cellular senescence. siRNA transfection was performed
using Lipofectamine 2000 (LifeTechnologies) following
manufacturer’s instructions. siRNA was obtained from
Origene, (cat#SR413228), three different siRNA duplexes
named 8a,8b,8c were used. Only 8b and 8c were able to
produce significant reduction in MVK expression. Lova-
statin was dissolved in 99% Ethanol at a concentration of
10mM and diluted to working concentration (50 μM) in
cellular media. LPS (Sigma) from E. Coli 055:B5 has been
dissolved in water in a stock concentration of 1 mg/ml
and diluted to working concentration of 1 μg/ml. Lova-
statin was applied for 24h and at the final 4h LPS was
added in combined experiments Lova + LPS.Real-time PCR
Total cellular RNA was extracted using TRI-reagent
(Sigma) following manufacturer’s instructions and retro-
transcribed using High-Capacity cDNA Reverse tran-
scription kit (Applied Biosystems). To quantify mRNA,
Taq-man probes for MVK, NALP3 and β-Actin (as cali-
brator), were used (Applied Biosystems). Raw fluorescent
data were converted to fold-increase using the software
LinRegPCR [12] corrected for the analysis of hydrolysis
probe [13], using the ΔΔCt method. In these calculations,β-Actin was used as internal standard and “scrambled”
samples used as reference.
Western blot
Cells were lysed in Lysis Buffer (LB: 300mM NaCl, 1%NP-
40, 50mM Tris-HCl pH 7.4, 1mM EDTA) for 15 minutes
in ice. Proteins were then quantified, using Bio-Rad
Bradford protein assay (Bio-Rad), loaded onto a 4-20%
gradient gel (Bio-rad) and electrophoretically separated.
Subsequently proteins were transferred to nitrocellulose
membrane (Bio-rad) incubated with NALP3 antibody
(1:500, Abcam) and HSP90 antibody as a loading control
(1:4000, Santa Cruz). Membranes were then incubated
with secondary antibody HRP-conjugated and then re-
vealed with Clarity ECL substrate (Bio-Rad) visualized
with ChemiDoc™ MP imager (Bio-Rad). NALP3 protein
expression was evaluated by densitometric analysis using
ImageJ software (NIH). NALP3 mean optical density
(O.D.) was then normalized to HSP90 average optical
density and then the normalized O.D. from cells treated
with scrambled siRNA (SCR) was set as 1 and other treat-
ment related to SCR.
Cell death analysis
The programmed cell death of BV-2 was evaluated by flow
cytometry using Annexin V (A) and Propidium Iodide
(PI) staining. Briefly, 48 hours after stimulation, BV-2 cells
were harvested from the plates with a cell scraper and
washed with PBS. After harvesting, BV-2 cells were
stained for 15 minutes with FITC-conjugated A and PI
(Annexin V-FITC Apoptosis Detection Kit, Immunostep)
following the manufacturer’s indications.
Fluorescence was acquired with a CyAn ADP analyzer
and Summit software (Beckman Coulter, Brea, CA), then
analyzed with FlowJo software (version 7.6, Treestar Inc.,
Ashland, OR). Debris was excluded from the plot based
on the scatter. Subsequently, apoptosis was characterized
on the basis of the positivity to Annexin V and/or PI.
Statistic
For real-time PCR analysis, experiments were performed
in 5 replicates and analysis of each experiment was exe-
cuted in triplicate wells. For Western Blot, experiments
were made in 4 replicates. For Cell Death analysis, experi-
ments were performed in 3 replicates. ANOVA followed
by Bonferroni correction was used to determine signifi-
cant changes between the samples, when p < 0.05. Stat-
istical analysis was performed using software Prism™
(Graphpad).
Results
In order to obtain an in vitro model of MVK deficiency,
the effects of silencing Mevalonate Kinase expression
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way were detected.
We transfected BV-2 cell line with two different MVK
specific siRNA sequences (8b and 8c) and evaluated MVK
mRNA and protein expression (Figure 1). After different
time-course experiments (data not shown) we found that
at 72h post-transfection MVK mRNA was reduced 10-
fold in cells treated with 8b siRNA and 6-fold with 8c
siRNA (Figure 1a, left). Correspondingly we found 40% re-
duction in MVK protein in 8b cells and 20% reduction in
8c cells (Figure 1b and c). In parallel, we evaluated the ex-
pression of NALP3, a key component of inflammasome
pathway. Interestingly we found that neither mRNA levels
nor protein levels were influenced by MVK silencing
(Figure 1a, right, b and d). In addition we measured
caspase-1 activity to confirm that inflammasome plat-
form was not activated. We found that siRNA treat-
ment did not significantly increase caspase-1 activity
72h after transfection compared to untreated cells
(Additional file 1: Figure S1a). Moreover, we found thatFigure 1 Analysis of inflammasome components expression after siRN
expression, right NALP3 expression. mRNA expression in cells trasfected wi
comparison with UNT, i.e. untreated condition, cells subjected to transfectio
subjected to transfection but without any siRNA. (c) Optical density calcula
* = p < 0.05(d) Optical density calculation of NALP3 expression.lowering MVK expression does not cause programmed cell
death, as assessed by Propidium Iodide (PI) and Annex V
(AnnV) staining. Using flow cytometry we found that un-
treated cells have 15.32 ± 1.32% double positive cell (posi-
tive for PI and AnnV), cells transfected with a “scrambled”
(SCR) sequence have 14.08 ± 0.7% double positive, 8b
transfected have 19.02 ± 0.96% and 8c transfected have
17.12 ± 1.04 double positive cells. The small differences in
percentage are not significant with p < 0.05 (data not
shown). We also tried to determine if the effect of lowering
MVK expression could be more significant after LPS treat-
ment, used as a trigger for inflammasome platform activa-
tion. We then examined caspase-1 activity in siRNA cells,
and we found that LPS treatment increased caspase-1 activ-
ity with all the different transfections, i.e. “scrambled”
siRNA or 8b or 8c, although to the same rate, demonstrat-
ing once more that lowering MVK protein content does
not influence NALP3 activity (Additional file 1: Figure S1b).
We also investigated the effect of Lovastatin treatment,
alone or in combination with LPS, on MVK expressionA treatment (a) ΔΔCt analysis of mRNA expression. Left MVK
th “scrambled” sequences were considered as reference. * = p < 0.05 in
n but without any siRNA (b) Representative western blot: UNT cells
tion of MVK protein levels. Scrambled (SCR) condition was set as 1.
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tein increased markedly both following stimulation with
Lovastatin alone and with Lovastatin plus LPS (Figure 2a
and b). Notably, only the combined treatment increased
NALP3 expression (Figure 2a and c).
Discussion
Our findings demonstrate that reduction in MVK protein
up to 40% does not cause activation of the inflammasome
and cell death. In one of the first work describing MKD, 3
different patients presented MVK protein levels lower
than healthy controls [14]. It is thus possible that a
“threshold” effect exists and below certain levels, the
shortage of enzyme activity becomes pathological, as it
could be hypothesized looking at our data on cell death
(i.e. the observed reduction in enzyme content is not
sufficient to cause cell death). Moreover, no improve in
lowering MVK protein content has been observed also
by combining the 2 siRNA used in this study (data notFigure 2 Analysis of inflammasome components expression after LOVA
condition (UNT), lovastatin (LOVA) 10μM, LPS 0.5 ng/ml, LOVA + LPS do
n.s.: non significant differences * = p < 0.05 (c) optical density calculation of Nshown). It is thus possible that below certain levels of
expression, cells do not survive. Although other experi-
ments are needed to confirm this speculation, the pre-
viously cited work on KO mice might lend indirect
support to this hypothesis [3]. In addition we propose
an alternative explanations. It is possible that the acti-
vation of the Unfolded Protein Response (UPR)/au-
tophagy might be caused by some MVK mutations that
alter the protein structure, as seen by Houten and co-
authors in 2002 [15]. However, this hypothesis remains
untested and further works are needed to verify this
mechanism.
It is also possible that the lack of inflammasome acti-
vation might be cell specific and thus other experiments
would be required to test different cell types. Intri-
guingly, in a recent paper Van De Burg and co-authors
[16] proposed that isoprenoid shortage leads to autoph-
agy induction. The authors used simvastatin treatment
in THP-1 and primary monocytes.+LPS treatment (a) representative western blot: untreated
uble treatment. (b) optical density calculation of MVK protein levels:
ALP3 protein levels: n.s.: non significant differences * = p < 0.05.
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response might be triggered by inhibiting the pathway,
through statins treatment (or MVK mutations). In this
line, using two different cell models (human airway
mesenchimal cells and human atrial fibroblasts), Ghavami
and co-authors demonstrated that simvastatin can activate
UPR and autophagy and that this effect could be reverted
by mevalonate administration but not by cholesterol sup-
plementation, pointing to a crucial role of MVK and prob-
ably isoprenoid shortage in autophagy induction [17,18].
Furthermore, our results show that lovastatin treatment in
BV-2 murine cells (Figure 2a and c) has a diametrically
opposed effect to what observed in MKD patients, as
shown by Houten et al. in 2002 [15], who found lower
protein expression in fibroblast of patients carrying MVK
mutations. Our results indeed show that lovastatin treat-
ment results in a global increase of MVK protein content,
up to fifteen times compared to untreated cells. Based on
these findings, the lovastatin model should be amended,
but also the siRNA model, at least in hour hands, was not
able to mimic the pathologic features. Increase in MVK
expression due to lovastatin, however, might be not suffi-
cient to compensate for lower mevalonate acid content
(substrate of MVK, probably reduced due to HMG-CoA
blockade), also resulting in activation of a defective au-
tophagic pathway [16-18]. So, we speculate that MVK pro-
tein levels could be important for NALP3 activation and
the role of autophagy and UPR response could be pivotal
in MKD and MA. However, as stated before, this remains
just hypothesis and further experiments are needed to
verify it.Additional file
Additional file 1: Figure S1. (a) caspase-1 activity, expressed as fold
increase related to scrambled siRNA transfected cells (SCR), in cells
transfected with 8b, 8c siRNA or left untreated (UNT). No statistical differences
were observed. (b) caspase-1 activity, expressed as fold increase related to
scrambled siRNA transfected cells (SCR), in cells transfected with 8b, 8c siRNA
or left untreated (UNT). * = p < 0.05 in respect to each “mock” treated
samples.Competing interests
The authors declare that they have no competing interests.
Authors’ contribuitions
FC conceived the experiments, performed RT-PCR and WB and drafted the
manuscript. EP performed cell death analysis. MR supervised experiments
and helped to write the manuscript. SC supervised experiments and helped
to write the manuscript. All authors read and approved the final manuscript.
Author details
1Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, via dell’Istria
65/1, 34137 Trieste, Italy. 2Department of Life Sciences, University of Trieste,
Via A. Valerio 28, 34127 Trieste, Italy.
Received: 9 April 2014 Accepted: 4 January 2015References
1. Neven B, Valayannopoulos V, Quartier P, Blanche S, Prieur AM, Debré M,
et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl
J Med. 2007;356:2700–3. doi:10.1056/NEJMoa070715.
2. Ruiz Gomez A, Couce ML, Garcia-Villoria J, Torres A, Souto A, Yagüe J, et al. Clinical,
genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase
deficiency. Pediatrics. 2012;129:e535–9. doi:10.1542/peds.2010-2192.
3. Hager EJ, Tse HM, Piganelli JD, Gupta M, Baetscher M, Tse A, et al. Deletion of a
single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD
syndrome. J Inherit Metab Dis. 2007;30:888–95. doi:10.1007/s10545-007-0776-7.
4. Marcuzzi A, Piscianz E, Girardelli M, Crovella S, Pontillo A. Defect in mevalonate
pathway induces pyroptosis in Raw 264.7 murine monocytes. Apoptosis.
2011;16:882–8. doi:10.1007/s10495-011-0621-1.
5. Marcuzzi A, Tricarico PM, Piscianz E, Kleiner G, Vecchi Brumatti L, Crovella S.
Lovastatin induces apoptosis through the mitochondrial pathway in an
undifferentiated SH-SY5Y neuroblastoma cell line. Cell Death Dis.
2013;4:e585. doi:10.1038/cddis.2013.112.
6. Frenkel J, Rijkers GT, Mandey SHL, Buurman SWM, Houten SM, Wanders RJA,
et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion
in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis
Rheum. 2002;46:2794–803.
7. Eisenbarth SC, Flavell RA. Innate instruction of adaptive immunity revisited: the
inflammasome. EMBO Mol Med. 2009;1:92–8. doi:10.1002/emmm.200900014.
8. Frenkel J, Houten SM, Waterham HR, Wanders RJ, Rijkers GT, Duran M, et al.
Clinical and molecular variability in childhood periodic fever with
hyperimmunoglobulinaemia D. Rheumatol Oxf Engl. 2001;40:579–84.
9. Drenth JP, Powell RJ, Brown NS, Van der Meer JW. Interferon-gamma and
urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic
fever syndrome. Eur J Clin Invest. 1995;25:683–6.
10. Drenth JP, Göertz J, Daha MR, van der Meer JW. Immunoglobulin D
enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta
as well as interleukin-1 receptor antagonist from human mononuclear cells.
Immunology. 1996;88:355–62.
11. Tricarico PM, Marcuzzi A, Piscianz E, Monasta L, Crovella S, Kleiner G.
Mevalonate kinase deficiency and neuroinflammation: balance between
apoptosis and pyroptosis. Int J Mol Sci. 2013;14:23274–88. doi:10.3390/
ijms141223274.
12. Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJ,
et al. Amplification efficiency: linking baseline and bias in the analysis of
quantitative PCR data. Nucleic Acids Res. 2009;37:e45–5. doi:10.1093/nar/gkp045.
13. Tuomi JM, Voorbraak F, Jones DL, Ruijter JM. Bias in the Cq value observed
with hydrolysis probe based quantitative PCR can be corrected with the
estimated PCR efficiency value. Methods. 2010;50:313–22. doi:10.1016/j.
ymeth.2010.02.003.
14. Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A,
Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause
hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet.
1999;22:175–7. doi:10.1038/9691.
15. Houten SM, Frenkel J, Rijkers GT, Wanders RJA, Kuis W, Waterham HR.
Temperature dependence of mutant mevalonate kinase activity as a
pathogenic factor in Hyper-IgD and periodic fever syndrome. Hum Mol
Genet. 2002;11:3115–24. doi:10.1093/hmg/11.25.3115.
16. Burgh R van der, Nijhuis L, Pervolaraki K, Compeer EB, Jongeneel LH, van
Gijn M et al. Defects in mitochondrial clearance predispose human monocytes
to interleukin-1β hyper-secretion. J Biol Chem jbc. 2013;M113.536920.
doi:10.1074/jbc.M113.536920
17. Ghavami S, Sharma P, Yeganeh B, Ojo OO, Jha A, Mutawe MM, et al. Airway
mesenchymal cell death by mevalonate cascade inhibition: integration of
autophagy, unfolded protein response and apoptosis focusing on Bcl2
family proteins. Biochim Biophys Acta. 2014;1843(7):1259–71. doi:10.1016/j.
bbamcr.2014.03.006.
18. Ghavami S, Yeganeh B, Stelmack GL, Kashani HH, Sharma P, Cunnington R,
et al. Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-
induced cell death of human atrial fibroblasts. Cell Death Dis. 2012;21;3:e330.
doi:10.1038/cddis.2012.61.
